SOURCE: BioVentrix

November 06, 2007 11:30 ET

BioVentrix Hires New President and CEO, Kenneth Miller

Veteran Healthcare Professional to Expand Market for Company's Heart Failure Awareness Initiatives

SAN RAMON, CA--(Marketwire - November 6, 2007) - CHF Technologies, Inc., d/b/a BioVentrix, San Ramon, California, announced the appointment of Kenneth Miller as the new President and Chief Executive Officer. Mr. Miller replaces Acting CEO, Arthur Bertolero, who co-founded BioVentrix and remains a member of the Company's Board of Directors.

Mr. Miller brings to BioVentrix an outstanding track record of general management experience and research and development success. He is accomplished at securing financing, setting and executing strategies and exceeding revenue and profit objectives. His most recent success was as VP of Sales and Marketing for Cholestech, a global diagnostics company focused on coronary heart disease and diabetes. During his tenure there, Cholestech was acquired by Inverness for $317 million. Prior to that, Mr. Miller served as COO of R2 Technology, a diagnostic imaging company, where he helped grow revenues from $3 million to $58 million in three years.

"Ken has the perfect credentials for this position," said Gerald Grayson, BioVentrix Board Member. "We are very fortunate to have his leadership skills and vision for the future."

"I am intrigued with the technology and direction that BioVentrix is taking in the treatment of Heart Failure," said Mr. Miller. "The products in our pipeline will address the underserved needs of thousands of patients suffering from this debilitating disease. With over $30 billion spent annually on heart failure, BioVentrix is poised to capture a generous market share."

Mr. Miller received his MBA in Pharmaceutical Marketing from Fairleigh Dickinson University in Teaneck, New Jersey, and a BS from Rutgers University. He resides with his family in Danville, CA.

About BioVentrix:

BioVentrix is a private corporation based in San Ramon, California. Its mission is to improve and expand on the surgical treatment of heart failure by left ventricular reconstruction, primarily through the development of less invasive approaches, and ultimately, catheter-based procedures. BioVentrix's Scientific Advisory Board and associated physicians include some of the country's leading surgeons and cardiologists. For more information, please visit www.bioventrix.com

Contact Information